Department of Science and Technology (DST), Government of India and Chennai-based Mediclone Biotech Pvt. Ltd have entered into a collaboration under which a new drug will be developed at Mediclone Biotech for dog bite victims to avoid rabies infection.

The research proposal undertaken by Mediclone Biotech is a proposal, which involves with Rs 20 crore financial inputs, out of which DST will fund 60%. The new drug, which will be developed, will be free from side effects and will be produced by biotechnological methods whereby product quality, availability and the price will be attractive.

In India, 10,000 people die per year due to rabies infection (dog bite). There are 3 million dog bites per year in India, as per the World Health Organization (WHO) reports.

The proposal has gone through all the evaluation of Government of India through the panel of scientist before its approval. A legal agreement was signed between DST and Mediclone. DST was represented by Dr. Samadhanam,  Advisor, DST and Mediclone Biotech was represented by A. Mathiyalagan, managing director. Mediclone is working on developing many other products including monoclonal antibodies based therapeutic tool for snakebite victims, which is another socially relevant scientifically advanced research.

Mediclone Biotech Pvt. Ltd. is a company engaged in biotechnology based education, research and manufacturing. The company has a state of the art infrastructure and research team hopeful of bringing up R&D based new products.